Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

被引：0

作者：

Yosuke Kawashima

Toshiyuki Harada

Yuka Fujita

Taku Nakagawa

Kana Watanabe

Naoto Morikawa

Kei Takamura

Kenya Kanazawa

Tomoya Kuda

Kazuhiro Usui

Akimasa Sekine

Akira Inoue

Shunichi Sugawara

机构：

[1] Sendai Kousei Hospital,Department of Pulmonary Medicine

[2] JCHO Hokkaido Hospital,Department of Respiratory Medicine

[3] National Hospital Organization Asahikawa Medical Center,Department of Respiratory Medicine

[4] Omagari Kosei Medical Center,Department of Thoracic Surgery

[5] Miyagi Cancer Center,Department of Respiratory Medicine

[6] Iwate Medical University School of Medicine,Division of Pulmonary Medicine, Allergy, and Rheumatology

[7] Obihiro Kosei Hospital,Department of Pulmonary Medicine

[8] Fukushima Medical University School of Medicine,Department of Pulmonary Medicine

[9] Naha City Hospital,Department of Respiratory Medicine

[10] NTT Medical Center Tokyo,Division of Respirology

[11] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine

[12] Tohoku University School of Medicine,Department of Palliative Medicine

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Carboplatin; Albumin-bound paclitaxel; Cisplatin; Gemcitabine; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：515 / 522

页数：7

共 50 条

[31] A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)
Asahina, Hajime
Oizumi, Satoshi
Takamura, Kei
Harada, Toshiyuki
Harada, Masao
Yokouchi, Hiroshi
Kanazawa, Kenya
Fujita, Yuka
Kojima, Tetsuya
Sugaya, Fumiko
Tanaka, Hisashi
Honda, Ryoichi
Kikuchi, Eiki
Ikari, Tomoo
Ogi, Takahiro
Shimizu, Kaoruko
Suzuki, Masaru
Konno, Satoshi
Dosaka-Akita, Hirotoshi
Isobe, Hiroshi
Nishimura, Masaharu
LUNG CANCER, 2019, 138 : 65 - 71
[32] Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Zhang, Y.
Zhu, J. Q.
Yue, D.
Zhao, X.
Zhang, Q.
Chen, H.
Wang, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
[33] A phase II study of weekly nab-paclitaxel in combination with cisplatin as neoadjuvant chemotherapy in patients (pts) with locally advanced esophageal squamous cell carcinoma (SCC).
Yun, Fan
Zhou, Xinming
Jiang, Youhua
Chen, Qixun
Huang, Zhiyu
Gong, Lei
Yu, Haifeng
Yang, Haiyan
Liu, Jinshi
Mao, Weimin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[34] Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study
Masato Karayama
Naoki Inui
Shigeki Kuroishi
Koshi Yokomura
Mikio Toyoshima
Toshihiro Shirai
Masafumi Masuda
Takashi Yamada
Kazumasa Yasuda
Takafumi Suda
Kingo Chida
Cancer Chemotherapy and Pharmacology, 2013, 72 : 445 - 452
[35] Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-na⟨ve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study
Karayama, Masato
Inui, Naoki
Kuroishi, Shigeki
Yokomura, Koshi
Toyoshima, Mikio
Shirai, Toshihiro
Masuda, Masafumi
Yamada, Takashi
Yasuda, Kazumasa
Suda, Takafumi
Chida, Kingo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 445 - 452
[36] Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease
Kenmotsu, Hirotsugu
Yoh, Kiyotaka
Mori, Keita
Ono, Akira
Baba, Tomohisa
Fujiwara, Yutaka
Yamaguchi, Ou
Ko, Ryo
Okamoto, Hiroaki
Yamamoto, Nobuyuki
Ninomiya, Takashi
Ogura, Takashi
Kato, Terufumi
CANCER SCIENCE, 2019, 110 (12) : 3738 - 3745
[37] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC)
Sugio, K.
Nagashima, A.
Nakanishi, R.
Uchiyama, A.
Inoue, M.
Osaki, T.
Yoshimatsu, T.
Takenoyama, M.
Hanagiri, T.
Yasumoto, K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[38] Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed
Ciunci, Christine A.
Reibel, Jacob B.
Evans, Tracey L.
Mick, Rosemarie
Bauml, Joshua M.
Aggarwal, Charu
Marmarelis, Melina E.
Singh, Aditi P.
D'Avella, Christopher
Cohen, Roger B.
Langer, Corey J.
CLINICAL LUNG CANCER, 2022, 23 (04) : E310 - E316
[39] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Yardley, Denise A.
Brufsky, Adam
Coleman, Robert E.
Conte, Pierfranco F.
Cortes, Javier
Glueck, Stefan
Nabholtz, Jean-Mark A.
O'Shaughnessy, Joyce
Beck, Robert M.
Ko, Amy
Renschler, Markus F.
Barton, Debora
Harbeck, Nadia
TRIALS, 2015, 16
[40] Weekly nab-paclitaxel plus carboplatin as neoadjuvant therapy for IIIA-N2 lung squamous cell carcinoma: A prospective phase II study.
Zhu, Jian-Quan
Zhang, Yu
Yue, Dongsheng
Zhao, Xiaoliang
Zhang, Qiang
Chen, Hui
Wang, Changli
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →